IF IT ’ S COVID
THINK
*
PAXLOVID is indicated in patients ≥ 18 years with mild-moderate COVID-19 , unless contraindicated . Review for drug-drug interactions . Commence within 5 days of symptom onset . 1 PBS restrictions apply . 2
PBS requires PAXLOVID to be used as the first-line oral COVID-19 antiviral
treatment 2 – 4 †
† unless contraindicated 2-4
The contraindications to PAXLOVID can be found using the : Product Information for PAXLOVID 1 Liverpool COVID-19 Drug Interaction Checker 5
If PAXLOVID ’ s contraindications cannot be managed , an alternative oral COVID-19 antiviral can be used with the following requirement : 4
Details / reasons of contraindications to PAXLOVID must be documented in the patient ’ s medical records 4
Visit www . pbs . gov . au for more information .
Scan the QR code for more information and resources on PAXLOVID .
PBS Information : Authority Required ( STREAMLINED ). Category : GENERAL – General Schedule ( Code GE ). For verified SARS-CoV-2 infection . Treatment must be initiated within 5 days of symptom onset . Refer to PBS Schedule for full authority information .
Warning : Nirmatrelvir with ritonavir has the potential for significant drug-drug interactions . Prescribers and dispensers should carefully review a patient ’ s concomitant medications .
This medicinal product is subject to additional monitoring in Australia . This will allow quick identification of new safety information . Healthcare professionals are asked to report any suspected adverse events at www . tga . gov . au / reporting-problems .
Alternatively , any adverse events which are experienced with PAXLOVID ® can be reported to Pfizer on 1800 675 229 or by email to AUS . AEReporting @ pfizer . com
BEFORE PRESCRIBING , PLEASE REVIEW PRODUCT INFORMATION AVAILABLE BY SCANNING THE QR CODE OR CALL 1800 675 229 .
References : 1 . PAXLOVID Product Information . 2 . Nirmatrelvir (&) Ritonavir PBS Schedule . Pharmaceutical Benefits Scheme ( PBS ). Available at : https :// www . pbs . gov . au / medicine / item / 12996B-13147Y . [ Accessed March 2024 ]. 3 . Paxlovid ® ( nirmatrelvir and ritonavir ) Pharmaceutical Benefits Scheme Factsheet – Updated March 2024 . Available at : https :// www . pbs . gov . au / publication / factsheets / covid-19-treatments / PBS-Factsheet-paxlovid-nirmatrelvir-and-ritonavir-March-2024 . docx . [ Accessed March 2024 ]. 4 . Lagevrio ® ( molnupiravir ) Pharmaceutical Benefits Scheme Factsheet – Updated March 2024 . Available at : https :// tinyurl . com / 3t47ayaw [ Accessed March 2024 ]. 5 . COVID-19 Drug Interactions . University of Liverpool , 2024 . Available at : https :// www . covid19-druginteractions . org / checker . [ Accessed March 2024 ].
© 2024 . Pfizer Australia Pty Ltd . Sydney , Australia . All rights reserved . This information is intended only for healthcare professionals . www . pfizer . com . au . Medical Information : 1800 675 229 . www . pfizermedicalinformation . com . au . PP-C1D-AUS-0136 . PFIZ0147 . March 2024 .